Trade

with

Bioline Rx Ltd
(NASDAQ: BLRX)
AdChoices
1.37
-0.01
-0.72%
After Hours :
-
-
-

Open

1.43

Previous Close

1.38

Volume (Avg)

161.75k (73.08k)

Day's Range

1.33-1.44

52Wk Range

1.32-3.34

Market Cap.

46.74M

Dividend Rate ( Yield )

-

Beta

2.90

Shares Outstanding

34.12M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -16.48M

    • Market Cap.

    • 46.74M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.90

    • Forward P/E

    • 18.38

    • Price/Sales

    • -

    • Price/Book Value

    • 1.72

    • Price/Cash flow

    • -2.50

      • EBITDA

      • -14.33M

      • Return on Capital %

      • -51.63

      • Return on Equity %

      • -66.68

      • Return on Assets %

      • -51.63

      • Book Value/Share

      • 0.80

      • Shares Outstanding

      • 34.12M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 7.29

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.26

        • Cashflow Estimate

        • 0.32

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 12.31

              • 2.92

              • Quick Ratio

              • 12.20

              • 2.35

              • Interest Coverage

              • -10.54

              • 38.02

              • Leverage Ratio

              • 1.20

              • 2.21

              • Book Value/Share

              • 0.80

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.56

                • 188.68

                • P/E Ratio 5-Year High

                • -12.56

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.49

                • 124.82

                • Price/Sales Ratio

                • -

                • 8.72

                • Price/Book Value

                • 1.76

                • 7.95

                • Price/Cash Flow Ratio

                • -2.50

                • 45.45

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -66.68

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -51.63

                        (-)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -60.90

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • -

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -16.46M
                      Operating Margin
                      -
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -2.50
                      Ownership

                      Institutional Ownership

                      -

                      Top 10 Institutions

                      171.84%

                      Mutual Fund Ownership

                      1.17%

                      Float

                      -

                      5% / Insider Ownership

                      -

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • FCP OP MEDICAL BioHealthTrends

                      •  

                        165,794

                      • 0.00

                      • 0.48

                      • I.B.I Global Equity

                      •  

                        84,000

                      • 5.00

                      • 0.25

                      • APO Medical Opportunities

                      •  

                        61,850

                      • 0.00

                      • 0.18

                      • Harel Selected BioMed

                      •  

                        49,000

                      • -9.26

                      • 0.15

                      • PHARMA/wHEALTH

                      •  

                        26,056

                      • 0.00

                      • 0.08

                      • RIM Global CC Bioscience

                      •  

                        13,600

                      • 0.00

                      • 0.04

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fcmi Financial Corp Et AL

                      •  

                        34,803,965

                      • +350.01%

                      • 144.12

                      • Sabby Management LLC

                      •  

                        2,021,347

                      • +6.23%

                      • 5.92

                      • SENVEST INTERNATIONAL LLC

                      •  

                        1,591,367

                      • +2.68%

                      • 4.66

                      • Bvf Inc

                      •  

                        1,501,000

                      • +87.62%

                      • 4.40

                      • OrbiMed Israel GP Ltd

                      •  

                        1,135,000

                      • -57.44%

                      • 4.70

                      • Orbimed Advisors, LLC

                      •  

                        1,135,000

                      • 0.00%

                      • 3.33

                      • Opaleye Management Inc

                      •  

                        650,000

                      • -55.20%

                      • 1.91

                      • Sphera Funds Management Ltd.

                      •  

                        600,000

                      • 0.00%

                      • 1.76

                      • Oppenheim Asset Mgmt Services S.à r.l.

                      •  

                        191,850

                      • +58.88%

                      • 0.56

                      • Medical Strategy GmbH

                      •  

                        165,794

                      • 0.00%

                      • 0.48

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      -

                      Style

                      Small Value

                      Bioline Rx Ltd was incorporated in April 2003. It is a clinical stage biopharmaceutical development company, engaged in identifying, in-licensing and developing therapeutic candidates that have advantages over currently available the...morerapies or that address unmet medical needs. The Company's development pipeline consists of six clinical-stage therapeutic candidates: BL-1040, a novel polymer solution for use in the prevention of ventricular remodeling following an acute myocardial infarction, or AMI; BL-8040, a novel peptide for the treatment of acute myeloid leukemia (AML), stem cell mobilization and other hematological indications; BL-7010, a novel polymer for the treatment of celiac disease; BL-5010, a customized, proprietary, pen-like applicator containing a novel formulation of two acids, which is...more being developed in Europe as a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease, or IBD; and BL-8020, an orally available treatment for the hepatitis C virus, or HCV, and other viral indications, with a unique mechanism of action involving the inhibition of virus-induced autophagy in host cells. The Company has three therapeutic candidates in the preclinical stages of development. The first therapeutic candidate, BL-1040, is a novel, resorbable polymer solution for use in the reduction or prevention of ventricular remodeling in patients who suffered an AMI. The second clinical-stage therapeutic candidate, BL-8040, is a novel, short peptide that functions as a high-affinity antagonist for CXCR4 used to develop for AML, stem cell mobilization and other hematological indications. The third clinical-stage therapeutic candidate, BL-7010, is a novel, non-absorbable, orally available, high-molecular-weight co-polymer used for the treatment of celiac disease.lessless

                      Key People

                      Dr. Kinneret Savitsky, PhD

                      CEO

                      Dr. Aharon Schwartz,PhD

                      Chairman of the Board/Director

                      Mr. Philip Serlin

                      CFO/COO

                      Mr. David Malek

                      Vice President, Divisional

                      Dr. Arnon Aharon, M.D.

                      Vice President, Divisional

                      • Bioline Rx Ltd

                      • 19 Hartum Street

                      • Jerusalem, 9777518

                      • ISR.Map

                      • Phone: +972 25489100

                      • Fax: +972 25489101

                      • biolinerx.com

                      Incorporated

                      2003

                      Employees

                      43

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: